

FMTVDM FRONTIER

Fleming Method for
Tissue and Vascular
Differentiation and
Metabolism



**FMTVDM - Patented
(U.S. Patent No. 9566037B2)**

Diplomatic Briefing: FMTVDM FRONTIER for OECD Nations

Subject: Strategic Integration of FMTVDM FRONTIER into OECD Health Systems

Prepared for: Ministries of Health, Research, and Innovation

I. Executive Summary

FMTVDM FRONTIER is the world's only patented platform for **absolute quantification** in PET/SPECT imaging. It enables reproducible, tissue-level diagnostics for cancer, cardiovascular disease, and inflammation—transforming clinical decision-making and public health strategy. This briefing outlines how FMTVDM FRONTIER aligns with OECD health priorities, offering a sovereign, licensed solution that advances precision medicine and global leadership.

Prepared by: Richard M. Fleming, PhD, MD, JD | Director, FMTVDM FRONTIER Consortium

II. Strategic Alignment with OECD Health Priorities

FMTVDM FRONTIER supports OECD's goals in precision medicine, health equity, and innovation.

 Table: OECD Health Goals vs. FMTVDM FRONTIER Capabilities

OECD Strategic Health Goal	FMTVDM FRONTIER Contribution
Precision Medicine	Provides quantifiable, reproducible imaging data for personalized diagnostics and treatment.
Health Equity	Reduces interpretive bias and ensures consistent diagnostics across diverse populations.
Innovation & Research	Enables reproducible data for clinical trials, AI integration, and scientific discovery.
Regulatory Validation	Supports evidence-based policy with standardized, quantifiable imaging metrics.
Cost-Effective Healthcare	Detects disease earlier, reducing long-term treatment costs and improving outcomes.
Global Health Leadership	Positions OECD nations as pioneers in diagnostic standardization and consortium-based research.

III. Licensing & Implementation Model

- **Sovereign Licensing:** Ministries retain control over sovereign deployment and data.
- **Consortium Access:** Participation in the FMTVDM Consortium for ongoing innovation.
- **Training & Support:** Includes clinician training, calibration protocols, and regulatory guidance.

Prepared by: Richard M. Fleming, PhD, MD, JD | Director, FMTVDM FRONTIER Consortium

IV. Diplomatic Opportunity

OECD nations can:

- Set global benchmarks for diagnostic excellence.
- Lead international collaborations on inflammation, cancer, and cardiovascular disease.
- Shape future health policy with validated, quantifiable data.

V. Call to Action

FMTVDM FRONTIER is ready for licensing and deployment. OECD ministries are invited to initiate diplomatic engagement, designate national imaging centers, and join the FMTVDM FRONTIER Consortium to shape the future of quantitative diagnostics.